IP Library Patent Application 11503881
Patent Application
App. No. 11/503,881

Assay for differentiating Alzheimer's and Alzheimer's-like disorders

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/503,881
Abstract

The invention relates to an assay for discriminating between Alzheimer's disease (AD) patients, patients with AD-Like disorders that express symptoms like AD, and non-demented age-matched controls (Normal). The method is based on the use of 2-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in blood serum, the quantitation of a group of identified biomarkers, and the biostatistical analysis of the concentration of the identified biomarkers to differentiate patients having AD from Normals and patients having other AD-Like disorders.

Claims (19)

1 . An assay for selecting appropriate biomarkers useful in diagnosis of Alzheimer's disease (AD) comprising:

a) collecting serum samples from patients with AD;

b) collecting serum samples from patients with an AD-Like disorder;

c) performing a two-dimensional gel electrophoretic analysis of the serum sample;

d) staining the two-dimensional gel;

e) quantitating a protein concentration in a plurality of protein spots on the two-dimensional gel; and

f) performing a statistical analysis on the quantities of the proteins in the protein spots to select a biomarker spot to distinguish between patient with AD from patients with the AD-Like disorder and normal controls.

2 . A screening assay for Alzheimer's disease (AD) comprising:

a) collecting a serum sample from a patient;

b) performing a two-dimensional (2D) gel electrophoretic analysis of the serum sample;

c) staining the 2D gel pattern;

d) quantitating a set of preselected protein spots; and

e) performing a statistical analysis on the quantity of the selected spots to determine the Likelihood of the patient having AD.

3 . An assay for differential diagnosis of Alzheimer's disease (AD) comprising:

a) collecting a serum sample from a patient;

b) performing a two-dimensional (2D) gel electrophoretic analysis of the serum sample;

c) staining the 2D gel pattern;

d) quantitating a set of preselected protein spots; and

e) performing a statistical analysis on the quantity of the selected spots to determine the Likelihood of the patient having AD as opposed to an AD-Like condition.

Assignments (6)
COURT ORDER Recorded Aug 14, 2012
From: NEOGENOMICS, INC., AKA NEOGENOMICS LABORATORIES
To: LOWELL T CAGE, TRUSTEE OF THE BANKRUPTCY ESTATE OF POWER3 MEDICAL PRODUCTS, INC
Reel/Frame 028788/0268 →
SALE BY COURT RECEIVER Recorded Mar 7, 2012
From: THE RECEIVERSHIP ESTATE OF POWER 3 MEDICAL PRODUCTS, INC.
To: NEOGENOMICS, INC. AKA NEOGENOMICS LABORATORIES
Reel/Frame 027831/0109 →
LEVY BY COURT RECEIVER Recorded Sep 19, 2011
From: POWER3 MEDICAL PRODUCTS, INC.
To: THE RECEIVERSHIP ESTATE OF POWER3 MEDICAL PRODUCTS, INC.
Reel/Frame 026930/0607 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2009
From: GOLDKNOPF, IRA L.; SHETA, ESSAM A.; FOLSOM, BRIAN R.
To: POWER 3 MEDICAL PRODUCTS, INC.
Reel/Frame 022989/0853 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2007
From: APPEL, STANLEY H.; YEN, ALBERT A.
To: POWER3 MEDICAL PRODUCTS, INC.
Reel/Frame 019798/0121 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2007
From: APPEL, STANLEY H.; YEN, ALBERT A.
To: BAYLOR COLLEGE OF MEDICINE
Reel/Frame 019808/0493 →